Journal and News Scan

In this brief report, the authors present an ex vivo bench study evaluating the impact of post-dilation strategies on Evolut FX+ transcatheter heart valves (23, 26, 29, and 34 mm). Valves were expanded in an elliptical annular model and underwent post-dilation using balloons either within or exceeding the instructions for use recommendations. Instructions for use-guided post-dilation preserved frame geometry, caused no leaflet damage, and maintained the regurgitant fraction below thresholds (<20 percent), remaining below 5 percent after 200 million accelerated wear cycles, simulating five years. In contrast, off-guidance balloon oversizing or inflation greater than two atmospheres caused waist overexpansion and leaflet tears at the skirt attachment site, with increased regurgitation. The authors conclude that excessive post-dilation may compromise leaflet integrity and durability. 

This individual participant data meta-analysis included 23 large double-blind randomized trials with a total of 154,664 participants. The authors systematically evaluated 66 adverse effects listed in statin product labels. In addition to the beyond established risks of muscle symptoms and new-onset diabetes, the analysis found that statins were associated with significant excesses in only four outcomes: abnormal liver transaminases, other liver function test abnormalities, urinary composition changes, and edema. The absolute annual excess risks were small, generally less than 0.1 percent. Liver enzyme elevations showed a dose-response relationship, particularly with high-intensity atorvastatin; however, these evaluations were not linked to serious clinical hepatobiliary events. No causal associations were found for most labeled effects, including cognitive impairment, depression, sleep disturbances, sexual dysfunction, neuropathy, or renal injury. The authors concluded that current labeling overstates the harms and should be revised to more accurately reflect randomized evidence. 

In this article, the authors present the three-year results of the randomized LYTEN trial comparing balloon-expandable valves (BEV; SAPIEN 3/ULTRA) and self-expanding valves (SEV; Evolut R/PRO/PRO+) for valve-in-valve transcatheter aortic valve replacement (TAVR) in failed small surgical aortic bioprostheses (≤23 mm). Among 98 patients, SEV showed superior hemodynamic performance at three years, with lower mean gradients (13.1 ± 8.6 vs 20.4 ± 9.1 mm Hg), larger indexed effective orifice areas (0.93 ± 0.32 vs 0.69 ± 0.27 cm²/m²), and higher intended valve performance (82.4 percent vs 27.6 percent). Moderate aortic regurgitation was rare (2.9 percent SEV and 0 percent BEV). Functional status, quality of life, and the composite of death, stroke, or heart failure hospitalization were similar between the groups. 

This study investigated whether antifibrotic therapy is associated with a reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). Using a large retrospective cohort from the Mayo Clinic spanning 2005 to 2022, the authors compared 3,313 IPF patients who did and did not receive continuous antifibrotic treatment for at least six months. After balancing the groups using propensity score weighting, they found that the incidence of lung cancer was significantly lower in patients treated with antifibrotics, 0.34 vs 1.25 cases per 100 person-years. Additionally, antifibrotic use was independently associated with a reduced risk of lung cancer (subdistribution hazard ratio 0.36, p = 0.02). Traditional risk factors, such as smoking history and higher forced vital capacity, were linked to a greater cancer risk. 
 
This article is important for the cardiothoracic surgery community because lung cancer commonly complicates IPF and often limits surgical options due to poor pulmonary reserve and high perioperative risk. Understanding that antifibrotic therapy may lower lung cancer risk could influence long-term management strategies, the timing of surgical intervention, and surveillance protocols in patients with fibrotic lung disease, making it highly relevant to CTSNet’s global audience.